PTC Therapeutics (FRA:BH3) Beta: 1.4318 (As of Jun. 26, 2026)


FRA:BH3 PTC Therapeutics Inc FRA:BH3
51 GF Score
Price €72.00
GF Value €30.00
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics Beta?

PTC Therapeutics FRA:BH3 +0.45% 51 Beta is 1.4318 as of Jun. 26, 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 51/100 and a GF Value™ of €30.00. The stock has 9 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), PTC Therapeutics's Beta is 1.4318.


PTC Therapeutics  (FRA:BH3) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


PTC Therapeutics Beta Related Terms


PTC Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Beta Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.18 0.74 -0.03 0.28

PTC Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 1.15 1.57 0.28 1.80

FRA:BH3 vs APGE, MIRM, RYTM: Beta Comparison

For the Biotechnology subindustry, PTC Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Beta falls into.


FRA:BH3
51GF Score
PTC Therapeutics Inc FRA:BH3
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.4318 mean?
PTC Therapeutics (FRA:BH3) has a Beta of 1.4318 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for PTC Therapeutics and its competitors.
Is PTC Therapeutics' Beta too high?
PTC Therapeutics' current Beta is 1.4318. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Beta compare to APGE and MIRM?
PTC Therapeutics' Beta of 1.4318 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for PTC Therapeutics and its competitors. PTC Therapeutics's current Beta is 1.4318. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Beta of 1.4318. The stock's GF Value™ is €30.00, compared to a current price of €72.00 — trading 140% above its estimated fair value. The current Beta is 1.4318. PTC Therapeutics' overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Beta is 1.4318 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €72.00 is trading 140% above its estimated GF Value™ of €30.00.

Key valuation signals for FRA:BH3:

  • Beta: 1.4318
  • GF Value™: €30.00 vs. price of €72.00 (140% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score

Get the complete analysis for FRA:BH3

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.00
Price
€30.00
GF Value